Subcutaneous phytonadione for reversal of warfarin-induced elevation of the international normalized ratio

Debbie C. Byrd, Mark A. Stephens, Gale Hamann, Craig Dorko

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The efficacy and safety of subcutaneous phytonadione in the treatment of patients with asymptomatic excessive International Normalized Ratio (INR) values secondary to warfarin therapy were evaluated. Patients at an outpatient anticoagulation clinic with an INR of 8 or more but less than 14 were given 1 mg of subcutaneous phytonadione, and patients with an INR of 14 or more but less than 20 received 2 mg. The patients were instructed to withhold warfarin therapy for the next 24 hours and to immediately report any bleeding complications. At subsequent visits, patients with an INR of 8 or more but less than 14 were given an additional 1 mg of subcutaneous phytonadione. Patients with an INR above 4.5 were instructed to withhold warfarin therapy for an additional 24 hours. Seventeen patients received the 1-mg dose (group 1), and four patients received the 2-mg dose (group 2). In group 1, the mean INR reduction was 49% at 24 hours and 72% at 48 hours and the INR was below 4.5 in 93% of patients at 48 hours. In group 2, the mean INR reduction was 67% at 24 hours and 85% at 48 hours and the INR was below 4.5 in 100% of patients at 48 hours. In four group-1 patients and one group-2 patient, the INR fell below 2.0 at 48 hours. No patients reported hemorrhagic or thrombotic complications. Subcutaneous phytonadione safely lowered excessively high INR values caused by warfarin therapy.

Original languageEnglish (US)
Pages (from-to)2312-2315
Number of pages4
JournalAmerican Journal of Health-System Pharmacy
Volume56
Issue number22
StatePublished - Nov 15 1999

Fingerprint

Vitamin K 1
International Normalized Ratio
Warfarin
Therapeutics
Ambulatory Care Facilities

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Health Policy

Cite this

Subcutaneous phytonadione for reversal of warfarin-induced elevation of the international normalized ratio. / Byrd, Debbie C.; Stephens, Mark A.; Hamann, Gale; Dorko, Craig.

In: American Journal of Health-System Pharmacy, Vol. 56, No. 22, 15.11.1999, p. 2312-2315.

Research output: Contribution to journalArticle

@article{b8a3c818925a48cba924d36dd23cc88a,
title = "Subcutaneous phytonadione for reversal of warfarin-induced elevation of the international normalized ratio",
abstract = "The efficacy and safety of subcutaneous phytonadione in the treatment of patients with asymptomatic excessive International Normalized Ratio (INR) values secondary to warfarin therapy were evaluated. Patients at an outpatient anticoagulation clinic with an INR of 8 or more but less than 14 were given 1 mg of subcutaneous phytonadione, and patients with an INR of 14 or more but less than 20 received 2 mg. The patients were instructed to withhold warfarin therapy for the next 24 hours and to immediately report any bleeding complications. At subsequent visits, patients with an INR of 8 or more but less than 14 were given an additional 1 mg of subcutaneous phytonadione. Patients with an INR above 4.5 were instructed to withhold warfarin therapy for an additional 24 hours. Seventeen patients received the 1-mg dose (group 1), and four patients received the 2-mg dose (group 2). In group 1, the mean INR reduction was 49{\%} at 24 hours and 72{\%} at 48 hours and the INR was below 4.5 in 93{\%} of patients at 48 hours. In group 2, the mean INR reduction was 67{\%} at 24 hours and 85{\%} at 48 hours and the INR was below 4.5 in 100{\%} of patients at 48 hours. In four group-1 patients and one group-2 patient, the INR fell below 2.0 at 48 hours. No patients reported hemorrhagic or thrombotic complications. Subcutaneous phytonadione safely lowered excessively high INR values caused by warfarin therapy.",
author = "Byrd, {Debbie C.} and Stephens, {Mark A.} and Gale Hamann and Craig Dorko",
year = "1999",
month = "11",
day = "15",
language = "English (US)",
volume = "56",
pages = "2312--2315",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "22",

}

TY - JOUR

T1 - Subcutaneous phytonadione for reversal of warfarin-induced elevation of the international normalized ratio

AU - Byrd, Debbie C.

AU - Stephens, Mark A.

AU - Hamann, Gale

AU - Dorko, Craig

PY - 1999/11/15

Y1 - 1999/11/15

N2 - The efficacy and safety of subcutaneous phytonadione in the treatment of patients with asymptomatic excessive International Normalized Ratio (INR) values secondary to warfarin therapy were evaluated. Patients at an outpatient anticoagulation clinic with an INR of 8 or more but less than 14 were given 1 mg of subcutaneous phytonadione, and patients with an INR of 14 or more but less than 20 received 2 mg. The patients were instructed to withhold warfarin therapy for the next 24 hours and to immediately report any bleeding complications. At subsequent visits, patients with an INR of 8 or more but less than 14 were given an additional 1 mg of subcutaneous phytonadione. Patients with an INR above 4.5 were instructed to withhold warfarin therapy for an additional 24 hours. Seventeen patients received the 1-mg dose (group 1), and four patients received the 2-mg dose (group 2). In group 1, the mean INR reduction was 49% at 24 hours and 72% at 48 hours and the INR was below 4.5 in 93% of patients at 48 hours. In group 2, the mean INR reduction was 67% at 24 hours and 85% at 48 hours and the INR was below 4.5 in 100% of patients at 48 hours. In four group-1 patients and one group-2 patient, the INR fell below 2.0 at 48 hours. No patients reported hemorrhagic or thrombotic complications. Subcutaneous phytonadione safely lowered excessively high INR values caused by warfarin therapy.

AB - The efficacy and safety of subcutaneous phytonadione in the treatment of patients with asymptomatic excessive International Normalized Ratio (INR) values secondary to warfarin therapy were evaluated. Patients at an outpatient anticoagulation clinic with an INR of 8 or more but less than 14 were given 1 mg of subcutaneous phytonadione, and patients with an INR of 14 or more but less than 20 received 2 mg. The patients were instructed to withhold warfarin therapy for the next 24 hours and to immediately report any bleeding complications. At subsequent visits, patients with an INR of 8 or more but less than 14 were given an additional 1 mg of subcutaneous phytonadione. Patients with an INR above 4.5 were instructed to withhold warfarin therapy for an additional 24 hours. Seventeen patients received the 1-mg dose (group 1), and four patients received the 2-mg dose (group 2). In group 1, the mean INR reduction was 49% at 24 hours and 72% at 48 hours and the INR was below 4.5 in 93% of patients at 48 hours. In group 2, the mean INR reduction was 67% at 24 hours and 85% at 48 hours and the INR was below 4.5 in 100% of patients at 48 hours. In four group-1 patients and one group-2 patient, the INR fell below 2.0 at 48 hours. No patients reported hemorrhagic or thrombotic complications. Subcutaneous phytonadione safely lowered excessively high INR values caused by warfarin therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033571038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033571038&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 2312

EP - 2315

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 22

ER -